Sponsored

Chimeric Therapeutics (ASX: CHM) to feature at Biotech Showcase 2024 - Kalkine Media

December 21, 2023 02:14 PM AEDT | By Sonal Goyal
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • Chimeric Therapeutics will be presenting at the Biotech Showcase 2024, which is due to held on 9 January 2024 in San Francisco.
  • The conference offers an opportunity for life science entrepreneurs to come together and discover the potential of innovative technologies in drug discovery.
  • The conference takes place every year in San Fransisco.

In the latest announcement, Chimeric Therapeutics (ASX:CHM) informed that it will be presenting at the Biotech Showcase 2024 being held in conjunction with JP Morgan Week. The event is schedule to take place on 9 January 2024 at Yosemite C, Hilton San Francisco.

Biotech Showcase is an investor conference produced by Demy-Colton and EBD Group. The focus of the conference is on driving advances in therapeutic development by offering a networking platform to the investors and executives that encourages partnership and investment opportunities. The conference happens every year in San Francisco.

The Chief Executive Officer of Demy-Colton Sara Demy highlighted that Biotech Showcase presents an opportunity to the life science investors and entrepreneurs to unite and discover the potential of groundbreaking technologies that will share the future of drug industry.

Here’s what CHM’s CEO commented on participation of CHM in the event:

CHM shares traded 3.70% up at AU$0.028 apiece at the time of writing on 21 December 2023 with a market cap of AU$19.46 million.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

5 ASX Companies Leveraging AI to Drive Growth in 2024



We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.